Literature DB >> 17763951

Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis.

Cansel Türkay1, Ozlem Yönem, Sema Arici, Ayhan Koyuncu, Mehmet Kanbay.   

Abstract

The renin-angiotensin system is suggested to be important in liver fibrogenesis. It induces hepatic stellate cell proliferation and up-regulates transforming growth factor beta-1 (TGF-beta1) expression. Matrix metalloproteinase-2 (MMP-2) is involved in extracellular matrix remodelling. Fibrosis, a consequence of most chronic liver diseases, may be the result of a disturbed balance between fibrogenesis and fibrolysis. The aim of this study was to investigate the effect of enalapril on liver fibrogenesis induced in rats by bile-duct ligation. Forty-seven rats were divided into two groups: bile-duct ligated (BDL) (n = 24) and BDL + enalapril (n = 23). Fibrosis was evaluated by the Knodell scoring system, and TGF-beta1 and MMP-2 were assessed with immunohistochemistry at the second, fourth and sixth weeks after bile-duct ligation. In the BDL group, TGF-beta1 increased by the second week and this increase continued through weeks 4 and 6. In the BDL + enalapril group, TGF-beta1 was significantly lower than the other group (P < 0.05). MMP-2 progressively decreased after week 2 in the BDL group. In the BDL + enalapril group, MMP-2 was significantly higher than the BDL group at the fourth and sixth weeks. These results suggest that enalapril reduces the liver tissue TGF-beta1 and has an ameliorating effect on the fibrosis markers TGF-beta1 and MMP-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763951     DOI: 10.1007/s10620-007-9941-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

Review 1.  The virtuosity of hepatic stellate cells.

Authors:  S L Friedman
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

2.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat.

Authors:  T Watanabe; M Niioka; A Ishikawa; S Hozawa; M Arai; K Maruyama; A Okada; I Okazaki
Journal:  J Hepatol       Date:  2001-10       Impact factor: 25.083

4.  Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.

Authors:  G Paizis; R E Gilbert; M E Cooper; P Murthi; J M Schembri; L L Wu; J R Rumble; D J Kelly; C Tikellis; A Cox; R A Smallwood; P W Angus
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

5.  Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats.

Authors:  M C Wright; R Issa; D E Smart; N Trim; G I Murray; J N Primrose; M J Arthur; J P Iredale; D A Mann
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

6.  Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system.

Authors:  L L Wu; A Cox; C J Roe; M Dziadek; M E Cooper; R E Gilbert
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

7.  The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Han-Ming Lu; Ding-Guo Li; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

8.  Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.

Authors:  S Kim; K Ohta; A Hamaguchi; T Omura; T Yukimura; K Miura; Y Inada; Y Ishimura; F Chatani; H Iwao
Journal:  J Pharmacol Exp Ther       Date:  1995-04       Impact factor: 4.030

9.  Colchicine in the treatment of cirrhosis of the liver.

Authors:  D Kershenobich; F Vargas; G Garcia-Tsao; R Perez Tamayo; M Gent; M Rojkind
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

10.  Molecular mechanism of stellate cell activation and therapeutic strategy for liver fibrosis.

Authors:  Norifumi Kawada
Journal:  Comp Hepatol       Date:  2004-01-14
View more
  6 in total

1.  Inhibition of ATIR by shRNA prevents collagen synthesis in hepatic stellate cells.

Authors:  Peihong Dong; Fujun Yu; Xufei Fan; Zhuo Lin; Yongping Chen; Ji Li
Journal:  Mol Cell Biochem       Date:  2010-08-12       Impact factor: 3.396

2.  Effects of treatment with enalapril on hepatotoxicity induced by acetaminophen in mice.

Authors:  Mariel R B Betto; Lais F Lazarotto; Tatiane T N Watanabe; David Driemeier; Carlos E Leite; Maria M Campos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-03       Impact factor: 3.000

3.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

4.  Effect of angiotensin-converting enzyme inhibitor, lisinopril on morphological and biochemical aspects of fibrotic liver regeneration.

Authors:  Aysha Ambreen; Sarwat Jahan; Satwat Malik
Journal:  Saudi J Gastroenterol       Date:  2016-11       Impact factor: 2.485

5.  Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.

Authors:  Lindsey J Reese; Diane S Tider; Alicia C Stivala; Dawn A Fishbein
Journal:  AIDS Res Treat       Date:  2012-11-01

6.  Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis.

Authors:  Qianqian Zhu; Na Li; Fang Li; Zhihua Zhou; Qunying Han; Yi Lv; Jiao Sang; Zhengwen Liu
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-03-23       Impact factor: 1.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.